OpenResearchAlpha

Seminars in Neurology · 12 Nov 2026

Acute Neurotoxicity Syndromes from Immunotherapy: Emergency and ICU Management

Caleb R. S. McEntire, Christine Tschoe, Giovanna S. Manzano, Christine A. Eckhardth-index 1

1
Citations
Crossref's count; others 0
0
Citations in 2026
so far
1
Leading author's h-index
Christine A. Eckhardt, in QAI's scholar index
100
References
works it cites, from open citation data

Citations by database

Each database indexes a different set of journals, preprints and books, so they are shown side by side rather than blended.

  • Crossref1
  • OpenCitations0
  • Europe PMC0

Citations per year

The current year is still counting.

  • 2026 so far0

Abstract

Abstract Advances in cancer immunotherapy have transformed survival outcomes and driven widespread adoption of these treatments. However, as the population receiving immunotherapy has grown, neurologic complications have increasingly emerged, with rates of 1 to 3% among patients receiving immune checkpoint inhibitors and 26.9% among chimeric antigen receptor (CAR) T cell therapy recipients across all FDA-approved products. This review focuses on the early recognition and acute management of neurologic toxicities associated with immunotherapy, with particular emphasis on immune effector cell–associated neurotoxicity syndrome (ICANS) related to CD19 and BCMA-directed CAR T cell therapies. Herein we synthesize current understanding of clinical phenotypes and risk factors for severe neurotoxicity, and review evidence-based approaches to diagnostic evaluation, including neuroimaging, electroencephalography, and laboratory markers. Practical management strategies for severe cases are discussed, including corticosteroid initiation, cytokine-directed immunomodulatory therapies, exploratory therapies, and neurocritical supportive care for fulminant cerebral edema and status epilepticus. We address less common but high-risk neurologic complications associated with CAR T cell therapy beyond ICANS. Lastly, we touch upon key clinical findings and treatments for acute neurologic complications related to immune checkpoint inhibitors, bispecific T cell engagers, tumor-infiltrating lymphocyte therapy, and engineered T cell receptor therapies.

What the data shows

  • Crossref counts 1 citations, the most of the databases. The others count 0.
  • Christine A. Eckhardt has the highest h-index among the authors (1).

Graph

This paper in the middle, its authors and their most-cited papers below, the papers it cites to the left and the papers citing it to the right. The timeline lays every paper out by year.

Citing paper shares an authorAuthor without a profileSize shows citations, or h-index for authors

Select a node for its details. Drag to pan, scroll to zoom, drag a node to move it.

Start with

Authors (4)

Each author's standing in QAI's scholar index: the works their ORCID iD is attached to, and for anyone whose ORCID record names a lab OpenResearch follows, their arXiv preprints matched by name and a shared co-author. Names are as printed on the paper.

ProfileMost-cited paper

Cited by 0 papers

Who cites this paper, from open citation data, with Crossref's record of each; the 100 newest when there are more.

0 shown
No citing papers for this filter.

References (100)

What it cites, from open citation data, with Crossref's record of each.

Sign in to see 80 more references

A free account opens the rest of the citing papers and references on every paper’s page.